MEIS3

MEIS3 is a TALE-class homeodomain transcription factor that operates as a hub linking posteriorizing signals to neural and tissue patterning programs (PMID:20356957, PMID:14660437). It partners with PBX and HOX proteins, forming binary complexes with Pbx4 or Hoxb1b and a trimeric Pbx4–Meis3–Hoxb1b complex; this synergy to drive hindbrain fates requires intact PBX-interaction domains, and Meis3 binding to Pbx4 is itself required for Meis3 nuclear access (PMID:10679934, PMID:11262231). As a transcription factor it directly transactivates target enhancers through PBX–HOX binding motifs, demonstrated for a pax8 kidney-field enhancer (with Hoxb4 and Pbx1) and for posterior neural targets including HoxD1 and FGF3/FGF8 (PMID:36279927, PMID:19944089). In neural development, Meis3 is a direct transcriptional target of Wnt3a/beta-catenin signaling from adjacent paraxial mesoderm and is required downstream of Wnt3a to induce posterior nervous system fates (PMID:20356957); it establishes a hindbrain-inducing center by activating FGF/MAP-kinase signaling, which modulates the Wnt-PCP pathway to drive convergent extension and hindbrain marker expression (PMID:14660437). A Meis3–Tsh1 repressive complex acts on the Meis3 promoter to terminate this Wnt/Meis3 feedback loop, permitting cell cycle exit and neuronal differentiation (PMID:22399680). Beyond neural induction, Meis3 controls neural crest cell migration, proliferation, and enteric nervous system development upstream of Shh signaling (PMID:26354419), regulates cell survival through direct activation of PDK1 (PMID:21059917), and contributes to cancer by binding allele-specific regulatory variants to drive target expression such as AGPS in esophageal carcinoma (PMID:41950565).

1. 2000 Medium

   Established the biochemical basis for MEIS3 function by showing it assembles into HOX/PBX transcription factor complexes rather than acting alone.

   Evidence In vitro protein binding assays with zebrafish Pbx4, Meis3, and Hoxb1b

   PMID:10679934

   Open questions at the time

   • In vitro binding only; no demonstration of complex on DNA or in vivo
   • DNA-binding specificity of the trimer not defined
2. 2001 High

   Connected MEIS3 complex formation to function and localization, showing PBX interaction is required both for hindbrain-promoting synergy and for MEIS3 nuclear access.

   Evidence Gain-of-function overexpression, domain mutagenesis, and subcellular localization assays in zebrafish embryos

   PMID:11262231

   Open questions at the time

   • Direct target genes of the synergistic complex not identified here
   • Mechanism coupling PBX binding to nuclear import unresolved
3. 2003 High

   Defined the downstream signaling output of MEIS3, showing it creates a hindbrain-inducing center via FGF/MAP-kinase activation feeding into Wnt-PCP-driven morphogenesis.

   Evidence Explant recombination assays, morpholino knockdown, and pathway inhibition in Xenopus

   PMID:14660437

   Open questions at the time

   • Direct FGF target genes not yet identified at this stage
   • Molecular link between MEIS3 and PCP components indirect
4. 2004 Medium

   Placed MEIS3 in the retinoic acid caudalizing network and identified HoxD1 as a shared direct target, framing MEIS3 as a context-dependent integrator of patterning signals.

   Evidence Morpholino knockdown, explant assays, RA inhibition, and target gene analysis in Xenopus

   PMID:15196951

   Open questions at the time

   • Mechanism by which RA modifies MEIS3 activity not defined
   • Direct binding to HoxD1 regulatory elements not shown
5. 2009 Medium

   Positioned MEIS3 within the neural specification cascade downstream of Pax3/Zic and identified FGF3, FGF8, and HoxD1 as direct targets, explaining its requirement for hindbrain, neural crest, and primary neuron fates.

   Evidence Morpholino knockdown, ectopic expression rescue, and target gene analysis in Xenopus

   PMID:19944089

   Open questions at the time

   • Direct enhancer binding for FGF3/FGF8 not mapped
   • Cooperating PBX/HOX partners at these targets not defined
6. 2010 High

   Identified the upstream inductive signal, showing Wnt3a/beta-catenin from paraxial mesoderm directly activates MEIS3 to induce posterior neural fate.

   Evidence Wnt3a loss-of-function, ectopic expression rescue, ChIP, and promoter analysis

   PMID:20356957

   Open questions at the time

   • beta-catenin/TCF binding sites in the Meis3 promoter not finely mapped
   • Tissue-specificity of Wnt-driven activation not fully resolved
7. 2010 Medium

   Extended MEIS3 function beyond patterning to cell survival by identifying PDK1 as a direct target linking it to the PI3K-Akt pathway in beta-cells and ovarian carcinoma.

   Evidence Knockdown/overexpression, direct target analysis, and survival assays in two cell types

   PMID:21059917

   Open questions at the time

   • Cofactors at the PDK1 promoter not identified
   • Generalizability across cell types beyond the two tested unknown
8. 2012 Medium

   Revealed an autoregulatory off-switch in which a MEIS3-Tsh1 repressive complex shuts down the Meis3 promoter to permit cell cycle exit and neuronal differentiation.

   Evidence Biochemical co-complex analysis, functional epistasis, and promoter repression assays in Xenopus

   PMID:22399680

   Open questions at the time

   • Structural basis of the Meis3-Tsh1 interaction not defined
   • Whether the same complex acts on other targets unknown
9. 2015 Medium

   Demonstrated a role in enteric nervous system development, placing MEIS3 upstream of Shh signaling in neural crest migration and proliferation toward the gut.

   Evidence Morpholino knockdown, migration and proliferation assays, and marker analysis in zebrafish

   PMID:26354419

   Open questions at the time

   • Direct Shh-pathway target genes of MEIS3 not identified
   • Whether the effect is cell-autonomous in crest cells unresolved
10. 2022 High

    Provided direct evidence for the enhancer-level mechanism, showing MEIS3 with Hoxb4 and Pbx1 transactivates a pax8 enhancer through defined PBX-HOX motifs in renal specification.

    Evidence Morpholino knockdown, enhancer deletion/mutagenesis reporter assays, and animal cap assays in Xenopus

    PMID:36279927

    Open questions at the time

    • In vivo occupancy of the endogenous Pax8-CNS1 enhancer not shown by ChIP
    • Selectivity over lhx1 mechanistically unexplained
11. 2021 Medium

    Identified an upstream epigenetic regulator of MEIS3, showing HOXA1 deposits activating histone marks at the MEIS3 enhancer in hepatocellular carcinoma.

    Evidence ChIP assay and dual-luciferase reporter assay in HCC cells

    PMID:33520978

    Open questions at the time

    • Single method for the HOXA1-MEIS3 link
    • Downstream MEIS3 effectors in HCC not defined
12. 2026 Medium

    Extended MEIS3's enhancer-binding role to cancer, showing allele-specific binding to a regulatory variant that drives AGPS expression through a MEIS3/AGPS/NF-kB axis in esophageal carcinoma.

    Evidence CUT&Tag-qPCR, EMSA, RNAi, xenograft models, and Western blotting in ESCC cells

    PMID:41950565

    Open questions at the time

    • Whether PBX/HOX partners participate at the AGPS variant not tested
    • Mechanism linking AGPS to NF-kB activation not fully resolved

• How MEIS3's binary versus trimeric PBX-HOX complex composition selects between activator and repressor outputs at distinct target enhancers remains undefined.
• No structural model of MEIS3 on DNA with partners
• Genome-wide direct binding map not established
• Rules governing context-dependent activation versus repression unknown